ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma
EudraCT number 2015-005053-12
Protocol number MK3475-204
Sponsor Merck Sharp & Dohme LLC, 126 East Lincoln Ave.,P.O.BOX 2000,Rahway, New Jersey 07065, United States of America
Indications Hemato-oncology
Diagnosis Hodgkin Lymphoma
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2017
Date of approval by Institute (SÚKL) 30.6.2017
Date of approval by EC 1.6.2017
Date of initiation CT in ČR 1.11.2017
Date of ending CT in ČR
Sites FN Brno,Interní hematologická a onkologická klinika ,Jihlavská 20,Brno,625 00
Všeobecná fakultní nemocnice v Praze,I. interní klinika - klinika hematologie VFN a 1. LF UK,U nemocnice 2,Praha 2,128 08 (discontinued)
FN Hradec Králové,IV. interní hematologická klinika LF UK,Sokolská 581,Hradec Králové - Nový Hradec Králové,500 05
FN Královské Vinohrady,Interní hematologická klinika,Šrobárova 1150/50,Praha 10,100 34
Fakultní nemocnice Ostrava,Klinika hematoonkologie,17. listopadu 1790,Ostrava,708 52 (discontinued)

‹‹ Back to list